TrialBritish journal of clinical pharmacology2019

Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.

Jianke Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.